Published 4 issues per year
ISSN Print: 0893-9675
ISSN Online: 2162-6448
Indexed in
Anaplastic Lymphoma Kinase in Human Cancer
ABSTRACT
The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. This review will discuss our current understanding of ALK in human cancer and the implication of recent results for treatment.
-
Zimmermann Arthur, Pseudotumors and Related Lesions of the Hepatobiliary Tract, in Tumors and Tumor-Like Lesions of the Hepatobiliary Tract, 2017. Crossref
-
White Morris F., Receptor Tyrosine Kinases and the Insulin Signaling System, in Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment, 2017. Crossref
-
White Morris F., Receptor Tyrosine Kinases and the Insulin Signaling System, in Principles of Endocrinology and Hormone Action, 2018. Crossref
-
Zimmermann Arthur, Pseudotumors and Related Lesions of the Hepatobiliary Tract, in Tumors and Tumor-Like Lesions of the Hepatobiliary Tract, 2016. Crossref
-
Chang Xing, Wang Junfang, Bian Jiang, Liu Zi, Guo Ming, Li Zengqiang, Wu Yingliang, Zhai Xin, Zuo Daiying, 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells, Toxicology and Applied Pharmacology, 450, 2022. Crossref